A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models-Reference-Cited by-同舟云学术

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Published:2010-01 Issue:1 Volume:9 Page:145-156
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Brown Jeffrey L.,Cao Z. Alexander,Pinzon-Ortiz Maria,Kendrew Jane,Reimer Corinne,Wen Shenghua,Zhou Joe Q.,Tabrizi Mohammad,Emery Steve,McDermott Brenda,Pablo Lourdes,McCoon Patricia,Bedian Vahe,Blakey David C.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis;Neuro-Oncology;2024-06-04

2. Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids;Biomedicine & Pharmacotherapy;2023-01

3. TIE2-high cervical cancer cells promote tumor angiogenesis by upregulating TIE2 and VEGFR2 in endothelial cells;Translational Oncology;2022-12

4. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition;Journal of Pharmacology and Experimental Therapeutics;2022-10-14

5. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors;ESMO Open;2022-10